Reports Q2 revenue $3.91B, consensus $3.87B. Viatris CEO Scott Smith said: “Obviously, I could not be more pleased with our overall execution in the second quarter-one of the strongest quarters we’ve had to date at Viatris. These results signal what we expect to be the beginning of a growth journey for Viatris and set us up well for future success. As proud as I am of our strong performance, the foundation the Company has built and the stability and predictability we believe have clearly been achieved, my focus is on the future trajectory of the Company. I’m pleased to say we believe we are currently on track to announce all planned divestitures in 2023, including at least one significant divestiture in the third quarter, possibly more. The Company has laid out clear capital allocation and business development priorities for Phase 2 and we are fully dedicated to meeting these priorities to propel Viatris up the value chain and increase our return of capital to shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTRS:
- Viatris announces FDA acceptance of GA Depot NDA
- Viatris backs FY23 revenue $15.5B-$16B, consensus $15.6B
- Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
- VTRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Novartis weakness on Entresto patent ruling ‘seems overdone,’ says JPMorgan